EUVIMEDEUVIMED entdecken
Open Access

Tumor-infiltrating lymphocytes as a predictive biomarker of cutaneous immune-related adverse events after immune checkpoint blockade in patients with advanced melanoma

Michael R Stephens, Maria S Asdourian, Ted V Jacoby, Nishi Shah, Leah L Thompson, Tracey Otto, Yevgeniy R Semenov, Kerry L Reynolds, Ryan J Sullivan, Ruth K Foreman, Steven T Chen

Journal of the American Academy of Dermatology · 2023

DOI: 10.1016/j.jaad.2023.01.040 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Academy of Dermatology, 2023. Verfasst von Michael R Stephens und 10 weiteren Autor:innen. Beteiligte Einrichtung: Harvard Medical School, Boston, Massachusetts; Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts; Harvard Combined Der…. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Melanoma. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 5 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAMS NIH HHS, NCI NIH HHS, Dermatology Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsMelanomaHumansLymphocytes, Tumor-InfiltratingBiomarkersImmunotherapyBiomarkers, Tumor

Stichwörter der Autor:innen

cutaneous immune-related adverse eventdermatologic toxicityimmune checkpoint inhibitorimmunotherapymelanomaprognostic biomarkerstumor-infiltrating lymphocytes

Substanzen

Immune Checkpoint InhibitorsBiomarkersBiomarkers, Tumor

Autor:innen und Institutionen

  • Harvard Medical School, Boston, Massachusetts; Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts; Harvard Combined Dermatology Residency, Boston, Massachusetts.
  • Harvard Medical School, Boston, Massachusetts; Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts.
  • Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts; University of Hawaii at Manoa John A. Burns School of Medicine, Honolulu, Hawaii.
  • Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts; Virginia Commonwealth University School of Medicine, Richmond, Virginia.
  • Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey.
  • Harvard Medical School, Boston, Massachusetts; Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts.

Förderung

  • NIAMS NIH HHS
  • NCI NIH HHS
  • Dermatology Foundation

Zitieren

APA

Stephens, M. R., Asdourian, M. S., Jacoby, T. V., Shah, N., Thompson, L. L., Otto, T., Semenov, Y. R., Reynolds, K. L., Sullivan, R. J., Foreman, R. K., & Chen, S. T. (2023). Tumor-infiltrating lymphocytes as a predictive biomarker of cutaneous immune-related adverse events after immune checkpoint blockade in patients with advanced melanoma. Journal of the American Academy of Dermatology. https://doi.org/10.1016/j.jaad.2023.01.040

Vancouver

Stephens MR, Asdourian MS, Jacoby TV, Shah N, Thompson LL, Otto T, et al. Tumor-infiltrating lymphocytes as a predictive biomarker of cutaneous immune-related adverse events after immune checkpoint blockade in patients with advanced melanoma. Journal of the American Academy of Dermatology. 2023. doi:10.1016/j.jaad.2023.01.040

BibTeX
@article{Stephens2023,
  author = {Stephens, Michael R and Asdourian, Maria S and Jacoby, Ted V and Shah, Nishi and Thompson, Leah L and Otto, Tracey and Semenov, Yevgeniy R and Reynolds, Kerry L and Sullivan, Ryan J and Foreman, Ruth K and Chen, Steven T},
  title = {Tumor-infiltrating lymphocytes as a predictive biomarker of cutaneous immune-related adverse events after immune checkpoint blockade in patients with advanced melanoma},
  journal = {Journal of the American Academy of Dermatology},
  year = {2023},
  doi = {10.1016/j.jaad.2023.01.040}
}
Kostenlos starten →